Drug Interactions between enoxaparin and valsartan
This report displays the potential drug interactions for the following 2 drugs:
- enoxaparin
- valsartan
Interactions between your drugs
enoxaparin valsartan
Applies to: enoxaparin and valsartan
MONITOR: The concomitant use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and heparin or low molecular weight heparins may increase the risk of hyperkalemia. ACE inhibitors, ARBs, and some heparins individually have been associated with increased potassium levels or hyperkalemia. Patients with renal impairment, diabetes, old age, and severe or worsening heart failure may be at a greater risk.
MANAGEMENT: Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin. Serum potassium and renal function should be checked regularly.
References (10)
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
- (2001) "Product Information. Avapro (irbesartan)." Bristol-Myers Squibb
- (2001) "Product Information. Teveten (eprosartan)." SmithKline Beecham
- (2001) "Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Micardis (telmisartan)." Boehringer-Ingelheim
- (2002) "Product Information. Benicar (olmesartan)." Sankyo Pharma
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Perazella MA (2000) "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med, 109, p. 307-14
- (2011) "Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America
Drug and food interactions
valsartan food
Applies to: valsartan
GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.
MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.
References (2)
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.